Axa’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Axa’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-28,522	Closed	-$614K	–	1386
2018 Q3	$614K	Hold	28,522	–	–	﹤0.01%	1114
2018 Q2	$1.22M	Buy	28,522 +18,611	+188%	+$852K	﹤0.01%	959
2018 Q1	$647K	Buy	+9,911	New	+$702K	﹤0.01%	1109
2016 Q2	–	Sell	-30,802	Closed	-$5.04M	–	1421
2016 Q1	$5.04M	Sell	30,802 -353	-1%	-$71.6K	0.02%	564
2015 Q4	$10.2M	Buy	31,155 +5,782	+23%	+$1.88M	0.04%	376
2015 Q3	$8.18M	Sell	25,373 -85	-0.3%	-$37.3K	0.03%	433
2015 Q2	$10.1M	Buy	25,458 +106	+0.4%	+$45K	0.04%	415
2015 Q1	$12.5M	Buy	25,352 +1,240	+5%	+$481K	0.05%	352
2014 Q4	$8.63M	Sell	24,112 -5,464	-18%	-$1.63M	0.03%	426
2014 Q3	$5.7M	Buy	29,576 +907	+3%	+$199K	0.02%	503
2014 Q2	$6.85M	Sell	28,669 -818	-3%	-$166K	0.03%	482
2014 Q1	$7.54M	Buy	29,487 +20,302	+221%	+$6.21M	0.03%	437
2013 Q4	$1.82M	Buy	+9,185	New	+$1.63M	0.01%	791

Other funds holding LUMO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa's LUMO Position: Q4 2018 in Review

Axa sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2018, closing a stake of 28,522 shares — an estimated $614K sold.

Axa first reported a position in LUMO in Q4 2013 and held it in 13 quarters. The position peaked at $12.5M in Q1 2015. 87 funds tracked by Wall St. Rank hold LUMO as of Q4 2018.

Axa reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Axa sold 28,522 Lumos Pharma, Inc. Common Stock shares in Q4 2018, an estimated $614K.
Axa first reported a position in Lumos Pharma, Inc. Common Stock in Q4 2013 and held it in 13 quarters.
Axa's Lumos Pharma, Inc. Common Stock position peaked at $12.5M in Q1 2015.
87 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2018.

Based on Axa's 13F filing for Q4 2018, filed 13 Feb 2019.